Portal de Periódicos da CAPES

US Food and Drug Administration’s Approval of Aripiprazole Tablets With Sensor

2018; Physicians Postgraduate Press, Inc.; Volume: 79; Issue: 3 Linguagem: Inglês

10.4088/jcp.18com12255

1555-2101

Daniel J. Lee, Tiffany Farchione, Mitchell Mathis, Javier Muñiz, Brendan M Muoio,

Health Systems, Economic Evaluations, Quality of Life

Article AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.The US Food and Drug Administration (FDA)'s recent approval of aripiprazole tablets with sensor (Abilify MyCite, Otsuka) was met with a myriad of reactions from the media and the public. Recent publications expressed a wide range of concerns regarding the product, such as its potential to infringe on patient privacy and autonomy, create an adversarial dynamic between clinician and patient, be used in medicolegal situations, or affect insurance coverage. We agree that these are important issues requiring a broad discussion. However, discussion of these issues to date has largely been obscured by sensationalism, exemplified by publication titles such as "Swallowing a Spy—The Potential Uses of Digital Adherence Monitoring" and "First Digital Pill Approved to Worries About Biomedical †Big Brother.†" We hope that this piece facilitates a more rational and measured dialogue surrounding the product's actual capabilities, FDA's decision to approve the product, and any ethical concerns raised by the product.